Waters CEO Says AI Is Already Fueling Lab Demand As Drugmakers Race to Accelerate Discovery

What happened

Waters Corporation reported third-quarter adjusted earnings of $4.10 per share and revenue of $1.767 billion, both above analyst estimates, and raised its full-year outlook. CEO Udit Batra said AI is increasing drugmakers’ experiments and demand for the company’s laboratory instruments and consumables.

Confirmed

Global impact / market context

More AI-generated drug candidates and experiments can require more laboratory testing, supporting sales of Waters’ instruments, consumables and chromatography columns. If that demand continues, it could lift revenue; the article also says GLP-1 drug testing and other customer needs contributed to growth.

Analyst inference

The article links Waters’ results to several sources of demand: AI-enabled drug research, GLP-1 testing, PFAS testing, generic pharmaceuticals in India and instrument replacements. It reports 9% organic revenue growth, or 10% in constant currency, but gives no separate sales figures for these drivers.

Confirmed

What to watch

1. Watch for Waters’ next reported revenue and outlook, which can show whether demand for laboratory instruments and consumables continues to support growth beyond this quarter. Analyst inference
2. Watch whether management provides further detail on how AI-related research affects orders for instruments, consumables and chromatography columns; the article does not quantify those sales. Analyst inference
3. Watch whether demand from GLP-1 testing, PFAS testing, generic pharmaceuticals in India and instrument replacements remains strong, since the CEO cited these as growth supports. Analyst inference

Evidence

• Original source link unavailable